EP2164960A2 - Plattform zur zuführung von virusnanopartikeln an zielzellen - Google Patents

Plattform zur zuführung von virusnanopartikeln an zielzellen

Info

Publication number
EP2164960A2
EP2164960A2 EP08754646A EP08754646A EP2164960A2 EP 2164960 A2 EP2164960 A2 EP 2164960A2 EP 08754646 A EP08754646 A EP 08754646A EP 08754646 A EP08754646 A EP 08754646A EP 2164960 A2 EP2164960 A2 EP 2164960A2
Authority
EP
European Patent Office
Prior art keywords
interest
compound
cells
plant viral
viral capsids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08754646A
Other languages
English (en)
French (fr)
Inventor
Stefan Franzen
Richard Guenther
Steven A. Lommel
Lina Loo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
North Carolina State University
University of California
Original Assignee
North Carolina State University
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North Carolina State University, University of California filed Critical North Carolina State University
Publication of EP2164960A2 publication Critical patent/EP2164960A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/38011—Tombusviridae
    • C12N2770/38023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/38011—Tombusviridae
    • C12N2770/38041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/38043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants

Definitions

  • Another aspect of the present invention is a method of delivering a compound of interest to the nucleus of cells of interest, which cells are in vitro or in a subject such as a mammalian subject in need thereof, comprising providing plant viral capsids having the compound of interest enclosed therein, the plant viral capsids further comprising: (i) a cell targeting compound coupled thereto and (U) a nuclear targeting compound coupled thereto; and then administering the plant viral capsids to the cells of interest or the subject in an amount effective for said compound of interest to be delivered to the nucleus (or other sub-cellular organelle) of said cells of interest (that is, not released in the cytoplasm, but releasted in the nucleus or other subcellular orgaganelle of interest).
  • Chemical modifications and functionalization may also be used to modify plant viral capsid cavities.
  • the cavity may be modified by addition of thiols with the potential to form disulfides or react with metals ⁇ e.g., cadmium, gold).
  • siRNA Short interfering RNA or silencing RNA
  • siRNAs are double-stranded RNA molecules that are 15 or 20 nucleotides in length, up to 25 or 30 nucleotides in length. siRNAs are known. See, e.g., US Patents Nos. 7,101,995; 6,977,152; and 6,974,680.
  • CXCR4 can be targeted with plant viral capsids coupled to CXCR4 targeting peptides.
  • CXCR4 up-regulation is associated with hypoxia-inducible factor- 1 (D. Zagzag, et al., Laboratory Investigation, 86:1221-1232 (2006)) and other hypoxia factors (M.Z. Ratajczak, et al., Leukemia, 20:1915-1924 (2006)).
  • Antagonists to CXCR4 have been designed based on C-terminal deletion mutants of SDF-I, a natural ligand. (Y. Tan, et al., Experimental Hematology, 34:1553-1562 (2006)).
  • the present invention provides a method of delivering a compound of interest to the nucleus of cells of interest, wherein release of the compound of interest from the plant viral capsids does not occur in the cytoplasm of a cell of interest, which is the site where efflux pumps are located and can function to remove the compound of interest from the cell of interest.
  • release of the compound of interest from the plant viral capsids is time-delayed by the intrinsic time constant for divalent ion transport from the virus interior to the exterior cytosol, protoplasm or solution.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
EP08754646A 2007-05-25 2008-05-22 Plattform zur zuführung von virusnanopartikeln an zielzellen Withdrawn EP2164960A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94027707P 2007-05-25 2007-05-25
PCT/US2008/006540 WO2008153725A2 (en) 2007-05-25 2008-05-22 Viral nanoparticle cell-targeted delivery platform

Publications (1)

Publication Number Publication Date
EP2164960A2 true EP2164960A2 (de) 2010-03-24

Family

ID=40130375

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08754646A Withdrawn EP2164960A2 (de) 2007-05-25 2008-05-22 Plattform zur zuführung von virusnanopartikeln an zielzellen

Country Status (3)

Country Link
US (1) US9061076B2 (de)
EP (1) EP2164960A2 (de)
WO (1) WO2008153725A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008153725A2 (en) * 2007-05-25 2008-12-18 North Carolina State University Viral nanoparticle cell-targeted delivery platform
CN102335139B (zh) * 2011-10-08 2013-02-13 南方医科大学 一种阿霉素缓释纳米颗粒及其制备方法
WO2013158620A1 (en) * 2012-04-16 2013-10-24 North Carolina State University Nanotechnology system for agricultural applications
WO2014130454A1 (en) * 2013-02-22 2014-08-28 Case Western Reserve University Non-covalent loading of plant picornavirus particles
US10881102B2 (en) 2015-05-18 2021-01-05 Zymtronix, Llc Magnetically immobilized microbiocidal enzymes
JP2018519838A (ja) * 2015-07-15 2018-07-26 ザイムトロニクス エルエルシーＺｙｍｔｒｏｎｉｘ， Ｌｌｃ 自動バイオナノ触媒製造
CA3031802A1 (en) 2016-08-13 2018-02-22 Zymtronix Catalytic Systems, Inc. Magnetically immobilized biocidal enzymes and biocidal chemicals
WO2023133422A1 (en) * 2022-01-04 2023-07-13 The Broad Institute, Inc. Compositions and methods for delivering cargo to a target cell

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021577A1 (fr) 1997-10-29 1999-05-06 Otsuka Pharmaceutical Co., Ltd. Compositions inhibant la proliferation des muscles lisses, procede de diagnostic de l'arteriosclerose et trousses correspondantes
US6410300B1 (en) 1998-01-12 2002-06-25 The University Of North Carolina At Chapel Hill Methods and formulations for mediating adeno-associated virus (AAV) attachment and infection and methods for purifying AAV
GB9825555D0 (en) 1998-11-20 1999-01-13 Imp College Innovations Ltd Suppression of xenotransplant rejection
US6495126B1 (en) 1999-07-20 2002-12-17 Mary Kay Inc. Treatment and composition for achieving skin anti-aging benefits by corneum protease activation
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
JP4641705B2 (ja) 2001-04-30 2011-03-02 ザイストール セラピューティクス， インコーポレイテッド 治療的タンパク質の亜細胞標的化
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
GB0120022D0 (en) 2001-08-16 2001-10-10 Photobiotics Ltd Conjugate
JP2006502091A (ja) * 2002-03-01 2006-01-19 イミューノメディクス、インコーポレイテッド クリアランス速度を高めるための二重特異性抗体点変異
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
CA2543257C (en) 2003-10-24 2013-12-31 Gencia Corporation Methods and compositions for delivering polynucleotides
US7824660B2 (en) 2003-12-05 2010-11-02 Buzatu Dan A Nanotubes for cancer therapy and diagnostics
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US20060216238A1 (en) 2005-02-28 2006-09-28 Marianne Manchester Compositions and methods for targeting or imaging a tissue in a vertebrate subject
BRPI0611976B1 (pt) 2005-06-24 2018-07-10 The University Of Melbourne Complexos iônicos
US20070258889A1 (en) 2005-11-09 2007-11-08 Montana State University Novel nanoparticles and use thereof
US8518419B2 (en) 2006-11-21 2013-08-27 Garvan Institute Of Medical Research Method of treating diabetes
WO2008153725A2 (en) * 2007-05-25 2008-12-18 North Carolina State University Viral nanoparticle cell-targeted delivery platform
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
WO2010059894A1 (en) 2008-11-21 2010-05-27 Bridge Pharma, Inc. Ocular formulations of norketotifen
US8518643B2 (en) 2010-02-04 2013-08-27 Pacific Biosciences Of California, Inc. Method to improve single molecule analyses
NZ702826A (en) 2010-03-11 2016-08-26 Wyeth Llc Oral formulations and lipophilic salts of methylnaltrexone

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008153725A2 *

Also Published As

Publication number Publication date
US9061076B2 (en) 2015-06-23
WO2008153725A2 (en) 2008-12-18
WO2008153725A3 (en) 2009-04-23
US20120039799A1 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
US9061076B2 (en) Viral nanoparticle cell-targeted delivery platform
US11660355B2 (en) Engineered extracellular vesicles for enhanced tissue delivery
KR101232377B1 (ko) 세포의 원형질체에서 유래한 마이크로베시클 및 이의 용도
CN107469088B (zh) 一种基于dna折纸术的精确识别靶向纳米载体的构建方法及其应用
US11883505B2 (en) Anticancer drug-containing plant virus particles
Rinoldi et al. Nanotechnology‐Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID‐19 Vaccines
Nuñez-Rivera et al. Brome mosaic virus-like particles as siRNA nanocarriers for biomedical purposes
CN111733139A (zh) 一种基于功能化巨噬细胞/单核细胞的靶向递送系统及其构建与应用
CN108175759A (zh) 一种抗肿瘤靶向给药系统及其制备方法与应用
JP2022548308A (ja) カーゴを標的細胞に送達するための組成物及び方法
US11371025B2 (en) Non-covalent loading of plant picovirus particles
JP7226803B2 (ja) 腫瘍の診断及び治療におけるｆｓｈホルモン受容体のリガンド
Yu et al. Multifunctional DNA polycatenane nanocarriers for synergistic targeted therapy of multidrug‐resistant human leukemia
AU2011205629B2 (en) Methods and compositions for nanoparticle-mediated cancer cell-targeted delivery
Cui et al. Gather wisdom to overcome barriers: Well-designed nano-drug delivery systems for treating gliomas
CN115998893A (zh) 一种肝脏靶向载药外泌体及应用和治疗肝脏疾病的药物
CN114958722B (zh) 一种结直肠靶向载药外泌体及应用和治疗结直肠疾病的药物
Yuan et al. Virus-like particle-based nanocarriers as an emerging platform for drug delivery
EP3145540B1 (de) Für krebs-targeting funktionalisiertes chemisch aktiviertes nanocapsid
Taschauer et al. Combined chemisorption and complexation generate siRNA nanocarriers with biophysics optimized for efficient gene knockdown and air–blood barrier crossing
CN116769717A (zh) 一种靶向外泌体及其制备方法和应用
Ferreira et al. Smart Targeted-Nanocarriers for Cancer Therapeutics
CN118105501A (zh) 一种在体构建CAR-M细胞疗法的靶向性mRNA-LNP递送系统及制法和应用
Jain Development of Protein Based PCBP2 siRNA Nanocomplex for Liver Fibrosis Therapy
Fleischmann et al. Biomedical nanoparticle design: What we can learn from viruses.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20091221

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

17Q First examination report despatched

Effective date: 20100316

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100928